Eltrombopag for newly diagnosed ITP patients
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with ITP for the first time (not a long-term case).
- Your platelet count must be 30 or lower (a very low level).
- You cannot be pregnant.
- You cannot have ITP caused by another illness (like lupus, hepatitis C, or H. pylori).
- You must not have severe bleeding (grade 3 or 4) or a history of recent infection or vaccination.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This study tests a sequence of two medicines that help raise platelet counts in people with severe ITP. The first is given as an injection, and the second is a pill, and they are given after standard steroid treatment. The goal is to see if this approach can improve platelet levels safely.
This study tests drugs called thrombopoietin agonists to help raise platelet levels in adults with ITP. It may help reduce bleeding risk and improve daily life.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.